Cambrex Cell Therapy. Buckingham Research Conference Call
|
|
- Elwin Jeremy Hudson
- 5 years ago
- Views:
Transcription
1 Cambrex Cell Therapy Buckingham Research Conference Call April 14, 2005
2 Safe Harbor Statement Today s presentation and discussion will contain forward-looking statements including statements regarding future operating performance, financial or revenue growth targets, or client project pipelines. These statements may be identified by words such as expects, anticipates, intends, estimates, believes or similar expressions. These statements are based on Cambrex s current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to materially differ from those set forth in the forward-looking statements. For discussion of these and other risks and uncertainties, see the Forward-Looking Statements and Risk Factors That May Affect Future Results sections in the Annual Report Form 10-K for the period ending December 31, The Company undertakes no obligation to update forward-looking statements. For further information, please refer to Cambrex s reports and filings with the Securities and Exchange Commission.
3 From Life Sciences to Specialty Pharma Biopharma Contract manufacturing Well positioned in growing life sciences industry Diversified technologies & capabilities Global manufacturing and distribution 31% 11% 58% Sound financials Outstanding regulatory compliance record Proven record of successful acquisition integration Bioproducts for Research, Therapeutics and Testing Human Health Small Molecule APIs and Intermediates 2005E Gross Sales: ~ $465 - $483M
4 From Drug Discovery to the Patient
5 Providing Differentiated Drug Development & Manufacturing Solutions General Technologies Organic chemistry Chiral synthesis Biologics Mammalian cell culture Microbial fermentation Yeast, bacterial Normal Human Cells Cell handling expertise and cell culture media Hematopoietic, mesenchymal stem cell systems Specialized Capabilities Controlled substances High potency and containment Radioisotope labeling Hazardous material handling Proprietary Technologies Taste masking Cytotoxicity testing Apoptosis screening Protein kinase assays Rapid microbial detection Endotoxin detection Mycoplasma detection Total viable organism
6 Secure Global Supply 10 cgmp facilities, plus cgmp pilot plants and kilo labs
7 Regulatory Compliance Excellence FDA inspections No 483 s EMEA TGA - Australian health authority Health Canada Italian Ministry of Health Irish Medicines Board Swedish Health Authority Belgium Ministry of Health Experience manufacturing approved APIs Over 100 customer audits annually
8 Sales 000$ Growth Target and Mix Organic Growth Acquisitions 22% Therapeutics/ Technology % Human Health 50% Human Health 39% Human Health % Biopharma 50% Biosciences 39% Biosciences 31% Bioproducts With Acquisitions
9 Leveraging Skills in New Directions: Specialty Pharmaceuticals Advance current partnerships in development e.g. Ortec International Acquire and/or develop pharmaceutical or biopharmaceutical products for niche markets Branded Mid- to late-stage clinical development Enhance products and extend product life cycle with niche technologies (e.g. taste masking)
10 Pharma Leadership John R. Leone President, CEO Large pharma experience in commercial operations Dan Marshak VP/CTO Industry expert and previously CTO, Osiris, a regenerative medicine company Dave Eansor President, Bioproducts Commercial experience at Cardinal Labs Dave Smith VP/Commercial Development Bioservices Large and emerging pharma sales and marketing experience
11 Cell Therapy
12 Cell Therapy Next generation therapeutics are here Potentially curative Localized delivery of therapeutic at target Cells readily available Regenerative rather than palliative Addresses problem not just symptoms Neurology stem cells for Parkinson s Cardiovascular muscle cells to replace damaged tissue (BioHeart) Addresses inherent problems with organ transplantation Limited organ availability Organ rejection Lifetime of immunosuppressive therapy
13 Cell Therapy Why Now? Regulatory FDA established separate division to review and approve cell therapies Technology New technologies allow for more viable products Automation for improved scaleup and manufacturing processes Release testing (rapid microbial testing, custom assays)
14 Traditional Basic Technologies Cell Therapy Technologies Minimally Manipulated Technologies Moderately Manipulated Technologies Complex Manipulation Technologies Blood Transfusion Autologous Bone Marrow Transplant Autologous: Critical Organ CNS Therapeutic Bone Matrix Autologous Blood Stem Cell Transplant Allogeneic: Homologous Cells Allogeneic: Non Homologous Cells Scaffold + Growth Factors Autologous: Topical or Peripheral Allogeneic: Blood Stem Cells Immunotherapy Cancer Vaccines Organ Transplants Devices with Living Cells Cell-Based Gene Therapy Regulatory Scrutiny/Time/Risk
15 Therapy Based on Cells Involved in Disease Neurological disorders: Parkinson s disease, spinal cord injury Cardiovascular disorders, myocardial infarction, congestive heart failure Insulin dependent diabetes mellitus Osteoarthritis Immune and hematological disorders Burns and wounds Disorders of the liver Macular degeneration Osteoporosis Muscular dystrophy Neurons Cardiomyocytes (heart muscle cells) Islet cells of the pancreas Cartilage cells Blood cells Skin cells Hepatocytes (liver cells) Retinal cells Bone cells Skeletal muscle cells
16 Worldwide Estimated Market Size of Cell Therapy and Related Technologies $81.3B $35.7B $20.2B Other Cell-based Cancer Vaccines Cell-based Gene Therapy Supporting Technologies Stem cell transplant Tissue Engineering Blood Transfusion Products Source: Jain PharmaBiotech Report 2004
17 Cambrex Cell Therapy Services
18 Clinical Cell-Based Services cgmp production facilities US 6 suites EU 4 suites Process development & media optimization units Cell culture media production Tissue acquisition infrastructure Support all types of therapies: Autologous, Allogeneic, Stem cells Integrated quality systems & regulatory services Assay development services Logistics support Raw material & release testing Sales, marketing and distribution services Validation services
19 Cell Therapy Manufacturing Pipeline Wound Healing (C3) Wound Healing Wound Healing (OrCel) Wound Healing Wound Healing Parkinson s Cardiovascular (BioHeart) Cancer Cardiovascular Renal Disease Cardiovascular Cardiovascular Spinal Cord PI PII PIII Registration Commercial
20 Some of Our Clients Ortec International Inc. Clinical Cell Culture Ltd.
21 Wound Care Market
22 Diabetic Foot Ulcers (DFU) Acute Wound Care Pressure Sores Venous Leg Ulcers (VLU) Treatment of Burns Advanced Wound Management Market Moist Antimicrobial Active Advanced Technologies Hydrogels Silver Biomaterials Tissue Engineering Alginate Growth Factors Scar Prevention Foam Stem Cell Transparent Film Skin Substitutes
23 Wound Care Market Market $ million in 2004, CAGR 11% through 2011 Hard-To-Heal VLU : 350,000 patients Hard-To-Heal DFU: 500,000 patients No. of Companies More than 20 Tiers of Competition Tier 1: Smith & Nephew (21.5%), J&J (16.5%), Tier 2: ConvaTec, 3M, Kinetic Concepts Tier 3: Novartis, Organogenesis, Fidia, Genzyme Biosurgery, Integra, Medline, Tyco, Urgo End Users Acute care hospitals, wound care clinics, long term facilities, home health facilities Competitive Factors Reimbursement, pricing, product innovation, treatment time, training
24 Accelerated Skin Regeneration and Wound Healing Keratinocytes and Growth Factors OrCel Epidermis Dermis Bi-layered -optimal growth factor mix Open collagen scaffold -deposited biomatrix -cell migration -re-vascularization Immature cells -highly productive -proliferative -induce rapid regeneration Cryopreserved -extended shelf life -ease of distribution Collagen Fibers, Fibroblasts and Growth Factors OrCel is a registered trademark of Ortec International.
25 OrCel Facts Improved Efficacy Accelerated wound closure Reduced healing time and pain No induced immune reactions Improved handling properties & delivery system Cryopreserved On-site availability Longer shelf-life Better manufacturing process Reimbursement code available Awaiting PMA Premarket approval (PMA) is the FDA process of scientific and regulatory review to evaluate the safety and effectiveness of Class III medical devices.
26 Cell Therapy Next generation therapeutics Regenerative rather than just palliative Avoids problems with organ transplant Regulatory pathway New technologies support commercially viable products
27 Cambrex Investment Highlights Well positioned in life sciences and transitioning to specialty pharma Above average growth potential Innovative products and services Diversified products and services base Leading positions in key segments Building on existing technologies and capabilities Moving towards higher growth opportunities Favorable demographics and regulatory environment for therapeutics New technologies for drug discovery and healthcare offer growth opportunities Proprietary products and technologies Development & manufacturing expertise Experience making licensed therapeutics Sales and marketing services Multiple routes to success Strong financial position
TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS
TISSUE ENGINEERING AND REGENERATION: TECHNOLOGIES AND GLOBAL MARKETS HLC101B August 2014 Yojana Jeevane Project Analyst ISBN: 1-56965-894-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA
More informationRegulation of advanced blood cell therapies
Regulation of advanced blood cell therapies www.pei.de Clinical trials using cell-based products Substantially manipulated cells and cells for non-homologous use Quality, safety and non-clinical aspects
More informationStem Cells, Regenerative Medicine and cgmp (GTP)
Stem Cells, Regenerative Medicine and cgmp (GTP) Encompass Stem cell based therapies activities Collection source Purification Isolation from other cell types if needed Manipulation Minimal vs Moderate
More informationAnika Therapeutics, Inc.
Anika Therapeutics, Inc. Jefferies Global Healthcare Conference June 4, 2015 Safe Harbor Statement The statements made in this presentation that are not statements of historical fact are forward looking
More informationThe NYSCF Research Institute
Regenerative Medicine Research Update Susan L. Solomon The NYSCF Research Institute New York Pharma Forum February 25, 2016 Regenerative Medicine Research Regenerative medicine uses laboratory grown human
More informationASX Small to Mid Caps Conference Singapore. May 27 th, 2010
ASX Small to Mid Caps Conference Singapore May 27 th, 2010 Mesoblast Capital Overview Fund Raisings $m IPO @ 50 cents 21.0 Equity Placements: Jul-06 17.4 Dec-07 13.4 Apr-09 10.8 May-10 37.0 Option funds
More informationAnika Therapeutics, Inc.
Anika Therapeutics, Inc. Canaccord Genuity 34th Annual Growth Conference August 14 th, 2014 Safe Harbor Statement The statements made in this presentation, which are not statements of historical fact,
More informationInvestor Presentation
Investor Presentation December 2013 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform
More informationRegenerative Medicine and Stem Cell Therapies
Regenerative Medicine and Stem Cell Therapies Regenerative Medicine Major component of successful regenerated / tissue engineered organs Scaffolds A critical element is the binding of the repopulating
More informationMesenchymal Stromal Cells Large-scale Culture
Mesenchymal Stromal Cells Large-scale Culture Adrian Gee Center for Cell & Gene Therapy Baylor College of Medicine Houston, Texas Hanley et al: Efficient manufacturing of therapeutic mesenchymal stromal
More informationLeading the world in novel adult stem cell therapies Half-Year Financial Results
Leading the world in novel adult stem cell therapies 2013 Half-Year Financial Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following
More informationJefferies 2015 Global Healthcare Conference June 3, 2015
Jefferies 2015 Global Healthcare Conference June 3, 2015 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationEMA s role & responsibility for the development of modern/advanced therapies
EMA s role & responsibility for the development of modern/advanced therapies Agenda Current regulatory picture Overall Regulatory framework New Committee at EMA Current Activities & Challenges Egbert Flory
More informationFor personal use only
ASX: LCT - OTCQX: LVCLY Diabetes Neurodegenerative Diseases Cell Encapsulation Six reasons to invest in Living Cell Technologies ALSIS 2012 #1 A company on a mission Cell based therapies to improve the
More informationCambrex Annual Analyst Meeting. The Harvard Club of New York City October 5, 2005
Cambrex Annual Analyst Meeting The Harvard Club of New York City October 5, 2005 1 Safe harbor statement Today s presentation and discussion will contain forward-looking statements including statements
More informationDeutsche Bank Health Care Conference
Deutsche Bank Health Care Conference May 8, 2018 NASDAQ: ANIK0 Safe Harbor Statement The statements made in, and during the course of, this presentation that are not statements of historical fact, including
More informationGeographical Distribution of the Tissue Engineering Market Regulatory Differences TABLE 3 DIFFERENCES IN REGULATORY APPROVAL: U.S. VS. EUR
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 1 SCOPE AND FORMAT... 2 METHODOLOGY AND INFORMATION SOURCES... 2 INTENDED AUDIENCE... 2 ANALYST CREDENTIALS...
More informationFujifilm s Initiatives in Regenerative Medicine
Fujifilm s Initiatives in Regenerative Medicine Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation March 30, 2015 Priority Business: Healthcare Expand business with focus on six core business
More informationSpecial Issue. Mesoblast Limited
Overview is an Australian biotechnology company committed to the commercialization of novel treatments for orthopedic conditions by using its unique adult stem cell technology for the regeneration and
More informationAlliqua BioMedical Investor Presentation August 2017 NASDAQ: ALQA
Alliqua BioMedical Investor Presentation August 2017 NASDAQ: ALQA Forward Looking Statements Safe Harbor Statement This presentation contains forward-looking statements. Forward-looking statements are
More informationFDA Regulatory, Compliance and Policy Developments: 361 HCT/Ps
FDA Regulatory, Compliance and Policy Developments: 361 HCT/Ps September 27, 2018 Presentation by: Elaine H. Tseng Partner FDA and Life Sciences Group King & Spalding Discussion with: Thomas Poché Vice
More informationJefferies 2018 Global Healthcare Conference. June 7, 2018
Jefferies 2018 Global Healthcare Conference June 7, 2018 Forward-Looking Statements Statements in this presentation regarding the future financial and operating results, outlook, growth, prospects, business
More informationINUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR REGENERATIVE MEDICINE
INUED DISCONTINUED DISCONTINUED DISCON MAKING THE IMPOSSIBLE POSSIBLE CENTER FOR > SOLUTIONS AND HOPE Millions of people worldwide suffer from deadly diseases, chronic conditions and congenital disorders
More informationRegulation of Cell and Gene Therapy Products in Canada
Regulation of Cell and Gene Therapy Products in Canada Canadian Blood and Bone Marrow Transplant Group June 8, 2018 Nadine Kolas, PhD Senior Policy Analyst Blood, Cells, Tissues and Organs Biologics and
More informationMolecular Medicine. Stem cell therapy Gene therapy. Immunotherapy Other therapies Vaccines. Medical genomics
Molecular Medicine Molecular Medicine Stem cell therapy Gene therapy Tumor therapy Immunotherapy Other therapies Vaccines Genetic diagnostics Medical genomics Medication Diagnostics medicine: old desire
More informationLeading the world in the development of adult stem cell therapies. June 2014
Leading the world in the development of adult stem cell therapies June 2014 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following the presentation,
More informationStem Cell Research From Bench to Bedside
Stem Cell Research From Bench to Bedside Stem Cell Dialogues Jan A. Nolta, Ph.D. Professor, Internal Medicine Director, UC Davis Institute for Regenerative Cures October 26, 2010 Stem Cells at UC Davis
More informationIntercytex Group plc
Intercytex Group plc 0 Disclaimer This information contained in this document is being supplied to you solely for your information and may not be copied, reproduced or further distributed to any person
More informationIndia as an Outsourcing Frontier in Biotechnology
1 India as an Outsourcing Frontier in Biotechnology K.V. Subramaniam President & CEO 3 rd Annual Biotech Supply Chain Academy Conference San Francisco Oct 26, 2010 Biotechnology Industry Issues Long gestation
More informationCommercializing Regenerative Medicine and the Importance of Collaboration September 7 th, 2012
Commercializing Regenerative Medicine and the Importance of Collaboration September 7 th, 2012 Scientia Advisors, LLC 55 Cambridge Parkway, Suit 300 Cambridge, MA 02142 www.scientiaadv.com 2012 Scientia
More informationInvestor Presentation RBC Capital Markets Global Healthcare Conference February 22, 2017
Investor Presentation 2017 RBC Capital Markets Global Healthcare Conference February 22, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private
More informationStephens Fall Investment Conference
Stephens Fall Investment Conference November 8, 2017 Steven M. Klosk President & CEO Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationStem Cells Canadian Perspective
Stem Cells Canadian Perspective John Laffey Critical Illness and Injury Research Centre, Keenan Research Centre, St Michael s Hospital. Departments of Anesthesia, Physiology and Interdepartmental Division
More informationThe Role of Adult Stem Cells in Personalized and Regenerative Medicine
The Role of Adult Stem Cells in Personalized and Regenerative Medicine Christopher J. Neill, Director of Corporate Operations American CryoStem Corporation Objective To illustrate the potential benefits
More informationJefferies 2017 Global Healthcare Conference. June 7, 2017
Jefferies 2017 Global Healthcare Conference June 7, 2017 Forward-Looking Statements This document may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationStem Cells & Neurological Disorders. Said Ismail Faculty of Medicine University of Jordan
Stem Cells & Neurological Disorders Said Ismail Faculty of Medicine University of Jordan Outline: - Introduction - Types & Potency of Stem Cells - Embryonic Stem Cells - Adult Stem Cells - ipscs -Tissue
More informationSCM Lifescience COMPANY PROFILE BUSINESS AREAS. [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea [Website]
SCM Lifescience [Address] 310, 366 Seohae-daero, Jung-gu, Incheon, Korea 22332 [Website] http://www.scmlifescience.com COMPANY PROFILE [Industry] SCM Lifescience is a research-based biopharmaceutical company
More informationCellular and Gene Therapy Products - CBER Update
DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTER FOR BIOLOGICS EVALUATION and RESEARCH Cellular and Gene Therapy Products - CBER Update Well Characterized Biological Products January 12-14, 2009 Kimberly
More informationThe Cell and Gene Therapy Catapult UK clinical trials database
The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)
More informationRegenerative Medicine. Speaker Disclosures. What is regenerative medicine? 6/22/2016
Regenerative Medicine Halland Chen, MD Speaker Disclosures I disclose that I am not a consultant or have any financial interests. 2 What is regenerative medicine? Regeneration of human cells, tissues,
More informationCalzada Ltd ASX:CZD. Presentation to Annual General Meeting 14 November 2012
Calzada Ltd ASX:CZD Presentation to Annual General Meeting 14 November 2012 Disclaimer This presentation is provided for general information purposes only. It is not intended to be relied upon as advice
More informationLongevity Leaders Conference. February 4, 2019
Longevity Leaders Conference February 4, 2019 Forward Looking Statements The matters discussed in this presentation include forward looking statements which are subject to various risks, uncertainties,
More informationUNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE MEDICINE
Massachusetts Institute of Technology Harvard Medical School Brigham and Women s Hospital VA Boston Healthcare System 2.79J/3.96J/20.441/HST522J UNIT CELL PROCESSES UNDERLYING TISSUE ENGINEERING AND REGENERATIVE
More informationEuropean Regenerative Medicine Firms & Their Strategic Approaches. Michael Morrison University of York
European Regenerative Medicine Firms & Their Strategic Approaches Michael Morrison University of York OVERVIEW Creating the European RM Universe of firms Characterizing the European RM Universe Strategic
More informationThe Cell and Gene Therapy Catapult UK clinical trials database
The Cell and Gene Therapy Catapult UK clinical trials database The UK clinical trials database covers cell and gene therapy clinical trial activities that the Cell and Gene Therapy Catapult (CGT Catapult)
More informationRegenerative Medicine Business Models
Regenerative Medicine Business Models Geoff Banda, Joyce Tait and James Mittra 23 May 2017 1 Business Models Value Chains Innovation Ecosystems 10 Case studies in the UK Private Firms (7) Public Organisations
More informationInnovating out of Crisis
Innovating out of Crisis Shigetaka Komori Chairman and CEO FUJIFILM Holdings Corporation 1 st June, 2015 Business Fields of Fujifilm Group Digital Camera Photo book Optical devise FY2015/3 Digital minilab
More informationDes cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
More informationTHE GLOBAL MARKET FOR STEM CELLS
THE GLOBAL MARKET FOR STEM CELLS BIO035F May 2016 Paul Evers Project Analyst ISBN: 1-62296-292-3 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free within the USA),
More informationMESENCHYMAL STEM CELLS ADVANCES & APPLICATIONS TABLE OF CONTENTS
MESENCHYMAL STEM CELLS ADVANCES & APPLICATIONS TABLE OF CONTENTS 1. REPORT OVERVIEW... 10 1.1 Statement of the Report... 10 1.2 Executive Summary... 12 2. INTRODUCTION... 14 2.1 Regenerative Medicine (RM)
More informationProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011
ProMetic Life Sciences Inc. Biotech Showcase San Francisco January, 2011 1 Forward Looking Statement / Copyright notice / Disclaimer Forward Looking Statement This presentation contains forward-looking
More informationDevelopment of Regenerative Medicine Products: FDA Perspectives
資料 3-3 Development of Regenerative Medicine Products: FDA Perspectives Steven R. Bauer, Ph.D. Chief, Cellular and Tissue Therapies Branch Office of Cellular, Tissue and Gene Therapies Center for Biologics
More informationRe: National Coverage Analysis (NCA) Tracking Sheet for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)
June 15, 2018 Katherine B. Szarama, PhD Lead Analyst Coverage and Analysis Group Centers for Medicare & Medicaid Services Department of Health and Human Services 7500 Security Blvd. Baltimore, MD 21244
More informationUnited Kingdom Tissue Engineered - Skin Substitutes Market Outlook to 2020
United Kingdom Tissue Engineered - Skin Substitutes Market Outlook to Reference Code: GDMECC0860DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationFDA Update. Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA
FDA Update Scott A. Brubaker, CTBS Director, Division of Human Tissues Office of Tissues and Advanced Therapies CBER/FDA 13 th Annual FDA and the Changing Paradigm for HCT/P Regulation February 13, 2017
More informationStem cells in Development
ANAT 2341 Embryology Lab 10 8 Oct 2009 Therapeutic Use of Stem Cells Practical Hurdles & Ethical Issues Stem cells in Development Blastocyst Cord blood Antonio Lee PhD Neuromuscular & Regenerative Medicine
More informationAjinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies
Ajinomoto s Pharma-related Business employing Leading-Edge Bioscience and Fine Chemical Technologies June 8, 2017 Hiroshi Fukushi Member of the Board & Corporate Senior Vice President General Manager,
More informationStem cells in Development
ANAT 2341 Embryology Lab 10 8 Oct 2009 Therapeutic Use of Stem Cells Practical Hurdles & Ethical Issues Stem cells in Development Blastocyst Cord blood Antonio Lee PhD Neuromuscular & Regenerative Medicine
More information20 years. Healed! What did he say? Just got home from the doctor. How s Dad?
2 0 1 2 A N N U A L R E P O R T How s Dad? Just got home from the doctor. What did he say? Healed! 20 years of stem cell research, development, and global leadership distilled into the only word that matters
More informationCorporate Presentation (TWSE 4743) Presented by Dr. Jui-Ching Chen, BD Director
Corporate Presentation (TWSE 4743) Presented by Dr. Jui-Ching Chen, BD Director November 28, 2018 Disclaimer The statements and contents included in this presentation that are not historical in nature
More informationAndrew Finnerty General Manager - CCMI
Andrew Finnerty General Manager - CCMI Manufacturing Human Mesenchymal Stem Cells for Clinical Trials Quality Considerations Biopharma and Pharma RQA Regional Forum Bioclin Laboratories, Athlone 13 May
More informationAdult Stem Cells for Chronic Pain. Dr. John Hughes, DO January 24 th, 2018
Adult Stem Cells for Chronic Pain Dr. John Hughes, DO January 24 th, 2018 Dr. John Hughes, DO Doctor of Osteopathy From Georgia Arizona College of Osteopathic Medicine - 2007 Aspen Integrative Medicine
More informationStem cells: Your future?
Stem cells: Your future? By: Vuk Devrnja, MD, MSc. International Medical Affairs Manager Cryo-Save Group www.cryo-save.com Who we are Umbilical Cord Blood and umbilical cord tissue are rich sources of
More informationWill Stem Cells Finally Deliver Without Controversy?
Will Stem Cells Finally Deliver Without Controversy? Keith Gary, Ph.D. Director of Program Development Kansas City Area Life Sciences Institute Olathe North Life Sciences 1 February 2012 What s the Buzz?
More informationOutcomes in Mesenchymal Stem Cell Manufacturing. Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL
Outcomes in Mesenchymal Stem Cell Manufacturing Athena Russell, MT(AAB) Human Cellular Therapy Laboratory Mayo Clinic Jacksonville, FL Background HCTL established in 1992 to support BMT programs of Mayo
More informationThe Science of Stem Cell Therapy
The Science of Stem Cell Therapy AVM Biotechnology City Centre Building 1420 Fifth Avenue, Suite 2650 Seattle, WA 98101 206-906-9922 www.avmbiotech.com Copyright 2008 AVM Biotechnology, LLC speaker disclosure
More informationStem Cells: Introduction and Prospects in Regenerative Medicine.
Stem Cells: Introduction and Prospects in Regenerative Medicine www.gothamgazette.com/.../stemcell/stem_cell.jpg Ode to a Stem Cell, Part II by VCW There once was stem cell stuck in the hood Dividing endlessly,
More informationTo our fellow shareholders,
BIOCARDIA, INC. To our fellow shareholders, Another year is completed and I remain optimistic about the strength of our therapeutic programs and the progress we are making. There is intense effort being
More informationFirst Quarter Trusted by the Life Sciences Industry
First Quarter 2018 Trusted by the Life Sciences Industry 1 Safe Harbor Forward Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties. Such
More informationKeeping cells under control
Keeping cells under control The critical role of standardisation in supporting innovation in regenerative medicine Standardisation is essential for ensuring the comparability and reliability of the measurements
More informationREMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research
REMEDiE Project London 7-8 May 2009 European Policies and Priorities for Stem Cell Research Charles Kessler European Commission DG Research, Health Directorate Outline of presentation Main features of
More informationDeveloping Targeted Stem Cell Therapeutics for Cancer. Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013
Developing Targeted Stem Cell Therapeutics for Cancer Shawn Hingtgen, Ph.D. Assistant Professor UNC Eshelman School of Pharmacy May 22 nd, 2013 The Challenge of Drug Delivery for Brain Cancer Stem Cells
More informationFDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC)
FDA Approach to the Regulation of Hematopoietic Stem/Progenitor Cells (HPC) Ellen Lazarus, M.D. Medical Officer Division of Human Tissues Office of Cellular, Tissue, and Gene Therapies FDA proposed approach
More information2016 North American Cell Therapeutics Technology Innovation Award
2016 North American Cell Therapeutics Technology Innovation Award 2016 Contents Background and Company Performance... 3 Industry Challenges... 3 Technology Attributes... 3 Conclusion... 8 Significance
More informationSpecial Report. medicine? Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D.
The new england journal of medicine Special Report Balancing Safety and Innovation for Cell-Based Regenerative Medicine Peter Marks, M.D., Ph.D., and Scott Gottlieb, M.D. Regenerative medicine is a field
More informationABOUT GLYCOSTEM. Company Overview
ABOUT GLYCOSTEM The company is a clinical stage biotech company established in the Netherlands in 2007. The company s headquarters and new state-of-the-art lab and production facilities are based at Pivot
More informationRecent Progress in ips Cell Research and Application
Recent Progress in ips Cell Research and Application Shinya Yamanaka, M.D., Ph.D. Center for ips Cell Research and Application (CiRA), Kyoto University, Japan Takeda - CiRA Joint Program, Shonan, Japan
More informationInvestor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER
Investor Overview Presentation ADVANCING LIFE SCIENCE TOGETHER Forward-Looking Statement Disclaimer In order to take advantage of the safe harbor provisions of the private securities litigation reform
More informationAll contents herein are the sole property of MEDIPOST Co., Ltd. Any reproduction or distribution of this document without the written consent of
All contents herein are the sole property of MEDIPOST Co., Ltd. Any reproduction or distribution of this document without the written consent of MEDIPOST Co., Ltd is prohibited. Copyright c 2004-2011 MEDIPOST.
More informationDrug /Device Combinations: The Convergence of Pharmaceutical and Biomaterial Science
Drug /Device Combinations: The Convergence of Pharmaceutical and Biomaterial Science Are We Just Raising the Stakes for Industry, Regulators, and Decision Makers? David Ames Director, Health Economics
More informationHSCI: the first Russian public biotech company
HSCI: the first Russian public biotech company (expanding into new geographic markets) TEASER for Investor presentation (road-show for sale of 28.6 % of HSCI s increased share capital) June 2014 Disclaimer
More informationIntroduction to Cell/ Biomaterial Engineering
Introduction to Cell/ Biomaterial Engineering Module 3, Lecture 1! 20.109 Spring 2011! Topics for Lecture 1 Introduction to tissue engineering! motivation! basic principles + examples! Introduction to
More informationKRISANI BIO SCIENCES PVT. LTD.
KRISANI BIO SCIENCES PVT. LTD. Flat B2, 2 nd Floor, Suryateja Apartments, Hindi Nagar, Punjagutta, Hyderabad, Telangana 500078. Email: kkr@krisanibio.com. URL: www.krisanibio.com Contact Number: +91 98494
More informationBiopreservation Tools for Cells, Tissues and Organs
Biopreservation Tools for Cells, Tissues and Organs NASDAQ: BLFS Investor Presentation March 2018 Safe Harbor Statement Except for historical information contained herein, this press release contains forward-looking
More informationCell and gene therapy: scaling up and moving to mass production
EDITORIAL Cell and gene therapy: scaling up and moving to mass production Nigel Whittle In order to fulfil the promise of cell therapy, it is important that manufacture of these therapies can be industrialized
More informationPerkinElmer, Inc. JP Morgan Global Healthcare Conference. Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH
PerkinElmer, Inc JP Morgan Global Healthcare Conference Robert Friel, Chairman and CEO January 14, 2015 HUMAN HEALTH ENVIRONMENTAL HEALTH 2014 PerkinElmer FACTORS AFFECTING FUTURE PERFORMANCE & NON-GAAP
More informationAustralia takes lead, again
Australia takes lead, again 14 October 2008 News Image not found or type unknown Australia takes lead, again In a first-of-its-kind of decision Australian medical regulator National Health and Medical
More informationIntroduction to Cell and Biomaterial Engineering! Module 3, Lecture 1!! Spring 2014!
Introduction to Cell and Biomaterial Engineering! Module 3, Lecture 1!! 20.109 Spring 2014! Topics for Lecture 1! Introduction to tissue engineering! motivation! basic principles! examples! Introduction
More informationRXi Pharmaceuticals. BioPharm America September 26, 2017 NASDAQ: RXII. Property of RXi Pharmaceuticals
RXi Pharmaceuticals BioPharm America September 26, 2017 NASDAQ: RXII Forward Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationApril 7, Dear Ms Närhi,
European Commission DG Enterprise & Industry Unit F2 Pharmaceuticals Legal Proposal on Information to Patients ulla.narhi@ec.europa.eu 45 Avenue d Auderghem, Office 10/93 B 1049 Brussels - Belgium April
More informationSwissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia
Published: 07:00 04.10.2007 GMT+2 /HUGIN /Source: Santhera Pharmaceuticals Holding AG /SWX: SANN /ISIN: CH0027148649 Swissmedic Accepts Santhera's Filing of SNT-MC17 in Friedreich's Ataxia Liestal and
More informationWelcome to the 2007 Annual Meeting of Stockholders
Welcome to the 2007 Annual Meeting of Stockholders Forward-Looking Statement This presentation contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform
More informationAdvanced Therapy Medicinal Products: Role and Funtion of the CAT. Martina Schuessler-Lenz,M.D. Paul-Ehrlich Institut, Germany
Advanced Therapy Medicinal Products: Role and Funtion of the CAT Martina Schuessler-Lenz,M.D. Paul-Ehrlich Institut, Germany Paul-Ehrlich Institut, Langen, Germany -German Federal Agency for Sera and Vaccines
More informationA Next Generation Stem Cell Company
A Next Generation Stem Cell Company Dr. Ross Macdonald, CEO Cynata Therapeutics Limited Proactive Investor Lunch, March 2017 Important Information This presentation has been prepared by Cynata Therapeutics
More informationCell and Gene Therapy Catapult preclinical database
Cell and Gene Therapy Catapult preclinical database The UK Preclinical Database covers preclinical research activity concerning cell, gene and other advanced therapies that the Cell and Gene Therapy Catapult
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationJapan : Victoria Business Forum
Japan : Victoria Business Forum Silviu Itescu Chief Executive 25 August 2015 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following the
More informationBuilding on our specialty expertise. Shire acquires Transkaryotic Therapies Inc.
Building on our specialty expertise Shire acquires Transkaryotic Therapies Inc. "SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not
More information